I wanted to see what Moderna has accomplished, especially since BARDA doubled their contribution for Moderna’s Phase 3, so I went to https://en.wikipedia.org/wiki/Moderna. What caught my attention was “… given that an mRNA vaccine – efficacy issues aside – will always stimulate a level of antibody development in subjects.” This I assume is why Moderna’s Phases 1 & 2 were rapidly successful. The NIH Study Details at https://clinicaltrials.gov/ct2/show/NCT044050...amp;rank=1 has listed 30 participant exclusions. The world is full of people that have pre-existing conditions, which are the ones most effected by Covid-19 with hospitalities and/or death. It is imperative that any vaccine in Phase 3 trial be judicially tested, for everyone that will need it, for side effects and efficacy. This process should not be done at “Warp Speed”.

Side note: I wonder what BARDA’ return policy (if any) is on money not spent for failed vaccine trials.